Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer

2018150 citationsJournal Articlehybrid Open Access

Authors

Bernhard Grubmüller · Medical University of Vienna

Daniela Senn · Medical University of Vienna

Gero Kramer · Medical University of Vienna

Pascal Baltzer · Medical University of Vienna

David D‘Andrea · Medical University of Vienna

Karl Hermann Grubmüller · Karl Landsteiner University of Health Sciences

Markus Mitterhauser

Abstract

TTV on PSMA PET seems to be a reliable parameter for response assessment in mCRPC patients undergoing RLT and might overcome the limitations of RECIST in prostate cancer. Furthermore, the change in TTV was significantly associated with OS in our cohort.

Topics & Keywords

Prostate Cancer Treatment and Research Radiopharmaceutical Chemistry and Applications Peptidase Inhibition and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Journal of Nuclear Medicine and Molecular Imaging

Volume 46, Issue 5, pp. 1063-1072

DOI: 10.1007/s00259-018-4236-4

Field-Weighted Citation Impact: 11.91